DOP56 Ustekinumab maintained clinically meaningful improvement in health-related quality of life in patients with moderate to severe ulcerative colitis: Results from the UNIFI long-term extensionWilliam J. Sandborn, Silvio Danese, Yiying Zhou et al.|Journal of Crohn s and Colitis|2020Cited by 3
P565 Efficacy and safety of long-term treatment with ustekinumab in moderate–severe ulcerative colitis patients with delayed response to ustekinumab induction: Results from UNIFI 2-year long-term extensionB E Sands, Laurent Peyrin‐Biroulet, María T. Abreu et al.|Journal of Crohn s and Colitis|2020Cited by 2